Small Molecule Innovator CDMO Market Size, Share, Opportunities, And Trends By Product (Small Molecule API, Small Molecule Drug Product), By Customer Type (Preclinical, Clinical, Commercial), By Therapeutic Area (Cardiovascular Disease, Oncology, Respiratory Disorders, Neurology, Metabolic Disorders, Infectious Disease, Others), And By Geography - Forecasts From 2023 To 2028

  • Published : Aug 2023
  • Report Code : KSI061616036
  • Pages : 152

It is anticipated that the small molecular innovator CDMO market would expand rapidly throughout the projected period. Small molecular innovator CDMO companies work with pharmaceutical and biotech firms to design and produce small-molecule medications. These businesses provide a wide range of services, including formulation development, manufacturing, process development, analytical analysis, and drug discovery. Contract manufacturing organizations, or CDMOs, provide development as a crucial component of their services.

Opportunities for the small molecule innovator market to increase

The key factors driving the small molecular innovator CDMO industry include expanding pharmaceutical R&D expenditures, rising small molecule demand, and rising rates of cancer and age-related diseases. Small compounds are less costly than biological medications. Consequently, it is anticipated that rising consumer demand for affordable medicines would further drive small molecular innovator CDMO market growth. Furthermore, the pandemic also had a substantial impact on the world economy and continued to have an ongoing effect on several businesses which had led to the growth of the small molecular innovator CDMO market.

Growing elderly population

The main reasons for the increase in the aging population are the declining birth rate and rising life expectancy. Additionally, older adults require more surgical intervention than younger ones due to their increased risk of musculoskeletal injuries and chronic conditions which expands the small molecular innovator CDMO industry. As a result, worldwide product demand is driven by an aging population. For example, according to a report from the UN Department of Economic and Social Affairs (UNDESA), the number of individuals in the world who are 60 or older is expected to increase by 56%, i.e, from 901 million in 2015 to 1.4 billion in 2030. The number of senior citizens worldwide is anticipated to reach around 2.1 billion by 2050.

Technological advancements

The small molecular innovator CDMO market is expected to expand due to advanced production methods and procedures. With the help of cutting-edge operational strategies like continuous production, CMOs are expected to improve the efficiency of their manufacturing processes while lowering waste and expenses. It is projected that the adoption of new manufacturing methods by CMOs would be driven by the expansion of small and mid-sized pharmaceutical companies, which are responsible for an increasing proportion of new medication approvals.

Investment in R&D activities

Even if the expenses of R&D are always rising, there are fewer and fewer methods that provide useful outcomes. Projects using AP biologics and injectable capabilities have received funding from several pharmaceutical corporations. Additionally, pharmaceutical firms have been looking for suppliers of contract packaging, contract manufacturing, and contract quality testing services. Additionally, CMOs will need to invest more significantly to gain agility and quickly adapt to changes in the production setup as the turnaround time for formulations and technology grows further fueling the small molecular innovator CDMO market growth.

Growth potential for small molecule APIs

Small molecule APIs continue to be essential to many pharmaceutical products, which adds to their small molecular innovator CDMO industry. To develop API synthesis, contract manufacturers are also making large investments in cutting-edge technology and sophisticated production techniques. These small molecule APIs in the small molecular innovator CDMO market are being significantly fueled by the convergence of the aforementioned variables.

Nevertheless, the small molecular innovator CDMO market has grown remarkably as a consequence of CDMOs adopting more novel ways to enhance bioavailability and optimize drug product composition.

Increasing use in pharmaceutical companies

Pharmaceutical businesses are becoming more interested in outsourcing non-core tasks like drug research and manufacturing to concentrate on their core skills. As a result, CDMO is aggressively extending its manufacturing facilities. For instance, in May 2022, Catalent, Inc. increased the size of its U.S. production plant that creates large-scale oral dosages. These additions are anticipated to improve CDMO and pharmaceutical company collaboration in the production of novel small-molecule medications, supporting small molecular innovator CDMO market growth.

Growing use in oncology

The oncology sector is anticipated to be the largest small molecular innovator CDMO market shareholder and it is anticipated that it will continue to dominate over the forecasted period. The landscape of cancer medication development has been significantly impacted by the move towards a personalized therapy strategy, which entails creating individualized treatment regimens based on the genetic profiles of specific patients. Pharmaceutical firms have formed agreements with CDMOs to hasten the development of innovative small-molecule cancer treatments and thereby satisfy market needs as personalized medicine and targeted therapies have come into greater emphasis.

The Asia Pacific small molecular innovator CDMO market is projected to propel  

Technology advancements, low service costs, and the availability of trained labor at a cheaper cost than in developing nations are expected to drive regional small molecular innovator CDMO market growth. One of the major reasons anticipated to fuel the expansion during the forecast period is an increased regulatory focus on quality control for manufacturing. Asia Pacific is home to several regulatory organizations, including the Therapeutic Goods Administration (TGA) in Australia, and the Ministry of Food and Drug Safety (MFDS) in South Korea. These organizations make sure that the pharmaceuticals made in the nation are of the highest caliber. This helps the expansion of the local small molecular innovator CDMO market.

Market Key Developments

  • In January 2023, Thermo Fisher Scientific Inc. purchased Binding Site Group, a global supplier of specialized diagnostics, in January 2023 for US$ 2.8 billion.
  • In September 2022, At its location in Wuxi City, WuXi STA officially opened a new facility for developing and producing sterile lipid nanoparticle (LNP) formulations. Solid-state development, pre-formulation, and clinical through commercial drug product manufacturing are just a few of the many services offered by the integrated drug product platform CRDMO.
  • In June 2022, Lonza opened a brand-new production and clinical phase development facility at its small molecules plant in Bend, Oregon. It specializes in creating intermediates for pharmacological products as well as completed spray-dried dispersion (SDD) dosage forms with increased bioavailability 


  • By Product
    • Small Molecule API
    • Small Molecule Drug Product
  • By Customer Type
    • Preclinical
    • Clinical
    • Commercial
  • By Therapeutic Area
    • Cardiovascular Disease
    • Oncology
    • Respiratory Disorders
    • Neurology
    • Metabolic Disorders
    • Infectious Disease
    • Others
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Others
    • Europe
      • United Kingdom
      • Germany
      • France
      • Spain
      • Others
    • Middle East and Africa
      • Saudi Arabia
      • UAE
      • Israel
      • Others
    • Asia Pacific
      • Japan
      • China
      • India
      • South Korea
      • Indonesia
      • Thailand
      • Others


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Small Molecule API

5.3. Small Molecule Drug Product


6.1. Introduction

6.2. Preclinical

6.3. Clinical

6.4. Commercial


7.1. Introduction

7.2. Cardiovascular Disease

7.3. Oncology

7.4. Respiratory Disorders

7.5. Neurology

7.6. Metabolic Disorders

7.7. Infectious Disease

7.8. Others


8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others


9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Vendor Competitiveness Matrix


10.1. Outsourced Pharma

10.2. Eurofins Scientific

10.3. Lonza

10.4. Sai Life Sciences

10.5. Ardena

10.6. Recipharm

10.7. Cambrex

10.8. Merck Millipore

10.9. Catalent

Outsourced Pharma

Eurofins Scientific


Sai Life Sciences




Merck Millipore